FDA drug voucher program stirs safety concerns after patient death, staff exodus

The Food and Drug Administration’s new drug review voucher program is facing questions about its safety record and long-term viability after a patient died while taking one of the drugs enrolled in the initiative, and as roughly one-fifth of the agency’s drug center staff have departed over the past year.

Legal experts and pharmaceutical policy researchers say the program—announced through press releases rather than formal rulemaking—is changing how the FDA applies its drug safety and efficacy standards without altering the underlying federal law, leaving its future in doubt should a new administration choose to undo it.

The Food and Drug Administration’s new drug review voucher program is drawing criticism from legal experts and pharmaceutical researchers over safety concerns and doubts about whether the initiative will outlast the administration that created it.

The program, which operates through informal administrative guidance rather than formal rulemaking, has come under scrutiny after the agency removed some drugs from its approved list, citing safety concerns. A patient died while taking one of the enrolled medications.

The initiative is running parallel to a significant staffing contraction at the FDA’s drug review center, where budget cuts, buyouts, and retirements have reduced the workforce by roughly 20 percent over the past year. Critics say that combination—reduced oversight capacity alongside an accelerated, informally structured approval pathway—raises the risk of safety gaps the agency may not be positioned to detect.

Proponents say the program fills a genuine gap in the existing drug development pipeline, offering pharmaceutical companies an incentive to pursue treatments for diseases that otherwise receive limited research investment.

Durability questions

Dan Troy, who served as the FDA’s chief counsel under President George W. Bush, said federal law gives the commissioner broad discretion to reorganize the handling of drug reviews. But he cautioned that the program’s informal structure limits its staying power.

Troy cautioned that the program’s informal structure limits its staying power. The program could be easily reversed by a subsequent administration.

The voucher program is also placing additional pressure on an agency drug center where 20% of staff have left through retirements, buyouts, or resignations over the past year.

Kesselheim said the program alters how standards are applied without changing the underlying law.

The program alters how the FDA applies existing standards without changing the underlying law. Critics hope the approach will eventually return to more scientifically and legally sound principles.